CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2016—Myriad Genetics announced an expanded companion diagnostics research collaboration with AbbVie to support the development of AbbVie’s investigational PARP inhibitor, veliparib. Under the terms of the agreement, AbbVie will use Myriad’s CDx portfolio, myChoice HRD and new tumor tests, to help identify patients with non-small cell lung cancer who are likely to respond to treatment with the combination of veliparib and chemotherapy. The agreement builds on an existing companion diagnostic research collaboration established in November 2014, in which Myriad has been working with AbbVie to support phase three clinical studies of veliparib for patients with breast cancer or ovarian cancer.
Myriad Genetics, 801-584-3600